Revolutionizing Lung Cancer Detection: The Role of AI-Derived CAD Software

By Staff Writer

July 12, 2023

Artificial Intelligence (AI)-derived computer-aided detection (CAD) software may be a game-changer in the field of lung cancer screening. These technologies can potentially enhance the detection and measurement of lung nodules in CT scan images, making them a cost-effective solution. However, more evidence is needed to ascertain which technologies are the most clinically and cost-effective.

There is little clinical-effectiveness evidence available on any of the individual technologies which means that more research is needed to fully understand the potential benefits and drawbacks of these technologies. For example, the software could potentially identify more people with benign lung nodules, leading to unnecessary anxiety and CT surveillance. 

Despite these uncertainties, the potential benefits of AI-derived CAD software cannot be ignored. Not only can it potentially increase the detection of lung nodules, but it can also improve reporting of nodule characteristics, assess the growth of lung nodules, and reduce the time to review and report CT scans. 

NICE encourages centres using AI-derived CAD software as part of targeted lung cancer screening to continue generating evidence and sharing their findings. This will help to realise the full potential of these technologies and facilitate comparisons between different software.

Recommendations for further research on the effect of using the software on clinical decision making and the effect of using the software on scan review and reporting time, are listed in the guideline.

Reference url

Recent Posts

Zimislecel type 1 diabetes
   

Cell Therapy for Type 1 Diabetes: Vertex Trial Results and Market Potential

🚀 What if we could revolutionize Type 1 diabetes treatment?

Vertex Pharmaceuticals has made significant strides with its promising phase 1/2 trial results for **zimislecel**, a stem cell-derived therapy that not only restores insulin production but also drastically reduces severe hypoglycemic events. As phase 3 trials commence, this breakthrough could reshape care for T1D patients and potentially reduce long-term healthcare costs.

Curious to learn how zimislecel and other potential cell therapies may redefine diabetes management? Click to read more!

#SyenzaNews #biotechnology #HealthEconomics

biosimilar clinical approach
    

Biosimilar Clinical Approach

🚀 How is the EMA’s new biosimilar clinical approach changing the landscape of drug approvals in Europe?

With a focus on tailored clinical assessments, the EMA is streamlining the pathway for biosimilars by allowing analytical data to take precedence over large-scale comparative efficacy studies. This shift promises to enhance patient access to life-saving therapies while maintaining rigorous safety standards.

Dive deeper into the implications of this innovative regulatory approach and find out how it can impact health economics and market access.

👉 Read more in the full article!
#SyenzaNews #regulatoryaffairs #MarketAccess

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.